Potential roles of erythropoietin in the management of anaemia and other complications diabetes

Diabetes, Obesity and Metabolism

Volumn 10, Issue 1, 2008, Pages 1-9

  Khoshdel, Alireza ^a   Carney, Shane ^a   Gillies, Alastair ^a   Mourad, Adnan ^a   Jones, Bernard ^a   Nanra, Ranjit ^a   Trevillian, Paul ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Anaemia; Diabetes mellitus; Erythropoietin; Renal failure

Indexed keywords

BIGUANIDE DERIVATIVE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SULFONYLUREA DERIVATIVE; TRANSFERRIN;

AGE DISTRIBUTION; ANEMIA; BLEEDING TENDENCY; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG CONTRAINDICATION; DYSPNEA; ERYTHROCYTE LIFESPAN; FEVER; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; IRON DEFICIENCY; IRON OVERLOAD; KIDNEY FAILURE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARESTHESIA; PATHOPHYSIOLOGY; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PURE RED CELL ANEMIA; REVIEW; TRANSFERRIN BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VASOCONSTRICTION; VOMITING;

EID: 37349058648     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00711.x     Document Type: Review

References (59)

1. Brenner BM, Levine SA. Hematologic consequence of renal failure. In: Remuzzi G ed. The Kidney, Vol. 2, 6th edn. Boston: Saunders, 2000.
2. Bosman DR, Winkler AS, Marsden JT et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-499.
3. Gilbert R, Cooper M. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury. Kidney Int 1999; 56: 1627-1637.
4. Dikow R, Schwenger V, Schomig M et al. How should we manage anemia in patients with diabetes? Nephrol Dial Transplant 2002; 17 (Suppl. 1): 67-72.
5. Thomas MC, Cooper ME, Tsalamandris C et al. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005; 165: 466-469.
6. Ricera BM, Todaro L, Caputo S et al. Blunted erythropoietin response to anemia in type 1 diabetic patients. Diabetes Care 1999; 22: 647.
7. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
8. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1022.
9. Meer P, Lipsic E, Henning RH et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model for ischemia-reperfusion injury. Eur J Heart Fail 2004; 6: 853-859.
10. Wright GL, Hanlin P, Amin K et al. Erythropoietin receptor expression in adult rat cardiomyopathy. FASEB J 2004; 18: 1031-1033.
11. Thomas MC, MacIsaac RJ, Tsalamandris C et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: A cross-sectional audit. Nephrol Dial Transplant 2004; 19: 1792-1797.
12. Sasso FC, De Nicola L, Carbonara O et al. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 2006; 29: 498-503.
13. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney Int 2003; 64: 610-615.
14. Thomas MC, McSaac RJ, Tsalamadris C et al. Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 4359-4363.
15. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
16. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: Effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-1004.
17. Sempos CT, Looker AC, Gillum RF, McGee DL, Vuong CV, Johnson CL. Serum Ferritin and death from all causes and cardiovascular disease. The NHANES II Mortality Study. Ann Epidemiol 2000; 10: 441-448.
18. Thomas MC, MacIsaac RJ, Tsalamandris C, Jerums G. Elevated iron indices in patients with diabetes. Diabet Med 2004; 21: 798-802.
19. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999; 22: 1978-1983.
20. Horl WH. Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transplant 2002; 17 (Suppl. 11): 35-38.
21. Kim DJ, Kim YM, Yun YS et al. Therapeutic effect of recombinant human erythropoietin on anemia with erythropoietin deficiency in diabetic patients. Diabet Med 2003; 20: 661-664.
22. Silverberg DS, Wexler D, Blum M et al. Erythropoietin should be part of congestive heart failure management. Kidney Int 2003; 64 (Suppl. 87): s40-s47.
23. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16: 307-312.
24. Ritz E. Managing anaemia and diabetes: A future challenge for nephrologists. Nephrol Dial Transplant 2005; 20 (Suppl. 6): Vi21-vi25.
25. Ritz E, Haxsen V. Diabetic nephropathy and anaemia. Eur J Clin Invest 2005; 35 (Suppl. 3): 66-74.
26. Zokowska E, Tomasevski M. Erythropoietin administration in diabetic patients. Przegl Lek 2003; 60: 532-535.
27. Cotroneo P, Ricerca B, Todaro L et al. Blunted erythropoietin response to anemia in patients with type 1 diabetes. Diabetes Metab Res Rev 2000; 16: 172-176.
28. Spallone V, Maiello MR, Kurukulasuriya N et al. Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric type 2 diabetic patients? Diabet Med 2004; 21: 1174-1180.
29. Yun YS, Lee HC, Yoo NC et al. Reduced erythropoietine responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract 1999; 46: 223-229.
30. Ahn SH, Garewal HS. Low erythropoietin level can cause anemia in patients without advanced renal failure. Am J Med 2004; 116: 280-281.
31. Mancini DM, Kunavarapu C. Effect of erythropoietin on exercise capacity in anemic patients with advanced heart failure. Kidney Int 2003; 64 (Suppl. 87): S48-s52.
32. McGill JB, Bell DS. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 2006; 20: 262-272.
33. Thomas MC, Rampersad M. Anemia in diabetes. Acta Diabetol 2004; 41 (Suppl. 1): S13-s17.
34. Meer P, Lipsic E, Henning RH et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 2004; 6: 853-859.
35. Wright GL, Hanlon P, Amin K et al. Erythropoietin receptor expression in adult rat cardiomyocyte associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004; 18: 1031-1033.
36. Silverberg DS, Wexler D, Blum M. The effect of correction of anemia in diabetics and non-diabetics with severe resistant congestive heart failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-146.
37. Malyszko J, Malyszko JS, Borawski J et al. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995; 77: 133-143.
38. Akimoto T, Kusano E, Shigeaki M et al. The effect of erythropoietin on interlukin-1 beta mediated increase in nitric oxide synthesis in vascular smooth muscle. J Hypertens 1999; 17: 1249-1256.
39. Banerjee D, Rodriguez M, Nag M et al. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 2000; 57: 1895-1904.
40. Noguchi K, Yamashiro S, Matsuzaki T et al. Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits. Br J Pharmacol 2001; 133: 395-405.
41. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33: 894-899.
42. Beleslin-Cokic BB, Cokic VP, Yu X et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 2073-2080.
43. Kanagy N, Perrine MF, Cheung DK, Walker BR. Erythropoietin administration in vivo increases vascular nitric oxide synthase expression. J Cardiovasc Pharmacol 2003; 42: 527-533.
44. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-2979.
45. Bahlmann FH, Groot K, Spandau J et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926.
46. Bianchi R, Buyukakilli B, Brines M et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 2004; 101: 823-828.
47. Friedman EA, L'Esperance FA, Brown CD, Berman DH. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease. Kidney Int Suppl 2003; 87: S57-S63.
48. Spaia S, Pangalos M, Askepidis N et al. Effects of short-term rhEPO treatment on insulin resistance in hemodialysis patients. Nephron 2000; 84: 320-325.
49. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59: 538-548.
50. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-242.
51. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368: 947-953.
52. Mix TC, Brenner RM, Cooper ME et al. Rationale -Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005; 149: 408-413.
53. Holt R. Anemia in diabetes. Diabetes Obes Metab 2006; 8: 469.
54. Osborne WR, Ramesh N, Lau S, Clowes MM, Dale DC, Clowes AW. Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci U S A 1995; 92: 8055-8058.
55. Svensson EC, Black HB, Dugger DL et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum Gene Ther 1997; 8: 1797-1806.
56. Yanay O, Barry SC, Flint LY, Brzezinski M, Barton RW, Osborne WR. Long-term erythropoietin gene expression from transduced cells in bioisolator devices. Hum Gene Ther 2003; 14: 1587-1593.
57. Maruyama H, Higuchi N, Nishikawa Y et al. Kidney-targeted naked DNA transfer by retrograde renal vein injection in rats. Hum Gene Ther 2002; 13: 455-468.
58. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48: 1066-1076.
59. Vogeser M, Schiel X. Serum erythropoietin concentrations in patients with anemia -preliminary hemoglobin-related reference ranges. Clin Lab 2002; 48: 595-598.